Close Menu

Colorectal Cancer

News and reporting on colorectal cancer.

A new agreement with Gamma-Dynacare has made the test available to new customers.

Industry Briefs: Feb 19, 2009

Premium

Proactive, PSI:Bioloyg, Pressure BioSciences, Applied Biomics

BioArray Briefs: 2009.02.17

Premium

SQI Diagnostics, Olink Bioscience, Innova Biosciences, Copenhagen University, Fujirebio Diagnostics, Uppsala University, Integromics, Gene Logic, Ocimum Biosolutions

The three-year project, called Proactive, will be coordinated by Olink Bioscience of Uppsala, Sweden.

The data, which the company said represent the first proof of activity of an oral RNAi drug, set the stage for an investigational new drug application filing later this year.

IP Update: Feb 5, 2009

Premium

USPTO Publishes Seven RNAi-Related Patent Applications

Without specific guidance from the FDA regarding KRAS testing, drugmakers Bristol-Myers Squibb and Amgen are facing lower sales of their colorectal cancer drugs Erbitux and Vectibix, and may need to get creative in how they market their drugs to patients and doctors.

New Product Watch: Feb 3, 2009

Premium

Navigenics, ImaGenes, Ocimum Biosolutions

While Helicos and Rosetta Genomics rose, shares of Cepheid were hit by its forecast of lower revenues. But, overall, the GWDN Index managed to gain ground while the broader market fell.

Pages

Retraction Watch writes that a cancer researcher has had an eighth paper retracted.

Computational biologist James Taylor has died, according to Johns Hopkins University.

The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.

In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.